| Primary |
| Atrophic Vulvovaginitis |
100.0% |
|
| Endometrial Adenocarcinoma |
33.3% |
| Irritability |
33.3% |
| Toxic Shock Syndrome |
33.3% |
|
| Secondary |
| Hormone Replacement Therapy |
77.4% |
| Menopausal Symptoms |
12.3% |
| Vitamin Supplementation |
1.9% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Depression |
0.9% |
| Drug Use For Unknown Indication |
0.9% |
| Hot Flush |
0.9% |
| Hypertension |
0.9% |
| Mineral Supplementation |
0.9% |
| Night Sweats |
0.9% |
| Pain |
0.9% |
| Rheumatoid Arthritis |
0.9% |
|
| Breast Cancer |
37.0% |
| Breast Cancer Metastatic |
22.2% |
| Progesterone Receptor Assay Positive |
7.4% |
| Aggression |
3.7% |
| B-cell Lymphoma |
3.7% |
| Breast Cancer Female |
3.7% |
| International Normalised Ratio Decreased |
3.7% |
| Medication Error |
3.7% |
| Ovarian Cancer Metastatic |
3.7% |
| Overdose |
3.7% |
| Respiratory Failure |
3.7% |
| Toxic Skin Eruption |
3.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
15.7% |
| Rheumatoid Arthritis |
14.7% |
| Drug Use For Unknown Indication |
13.0% |
| Hypertension |
8.7% |
| Osteoporosis |
7.3% |
| Hormone Replacement Therapy |
5.3% |
| Depression |
4.0% |
| Fsh Decreased |
3.0% |
| Hypogonadism Female |
3.0% |
| Lh Blood Decreased |
3.0% |
| Insomnia |
2.7% |
| Multiple Sclerosis |
2.7% |
| Pain |
2.7% |
| Blood Cholesterol Increased |
2.3% |
| Epilepsy |
2.3% |
| Chronic Ischaemic Heart Disease, Unspecified |
2.0% |
| Hypothyroidism |
2.0% |
| Supplementation Therapy |
2.0% |
| Vitamin Supplementation |
2.0% |
| Acth Decreased |
1.7% |
|
| Pain |
7.8% |
| Renal Impairment |
7.8% |
| Vomiting |
7.8% |
| Herpes Zoster |
5.9% |
| Malaise |
5.9% |
| Palpitations |
5.9% |
| Urticaria |
5.9% |
| Vision Blurred |
5.9% |
| Arthropathy |
3.9% |
| Atrial Fibrillation |
3.9% |
| Cystitis |
3.9% |
| Death |
3.9% |
| Depression |
3.9% |
| Enterococcal Infection |
3.9% |
| Erythema |
3.9% |
| Generalised Erythema |
3.9% |
| Insomnia |
3.9% |
| Mucosal Inflammation |
3.9% |
| Pain In Extremity |
3.9% |
| Pelvic Fracture |
3.9% |
|
| Interacting |
| Hormone Replacement Therapy |
100.0% |
|
| International Normalised Ratio Decreased |
100.0% |
|
